share_log

15-12G: Notice of termination of registration of a class of securities under Section 12(g) (and amendment thereto)

15-12G: Notice of termination of registration of a class of securities under Section 12(g) (and amendment thereto)

15-12G：終止註冊
美股SEC公告 ·  07/30 16:24

Moomoo AI 已提取核心訊息

eFFECTOR Therapeutics, Inc. has officially filed a Form 15 with the United States Securities and Exchange Commission (SEC) to terminate its registration under Section 12(g) of the Securities Exchange Act of 1934 and to suspend its duty to file reports under Sections 13 and 15(d) of the same act. The company, with its principal executive offices located at 124 Washington Street, Suite 101, Foxboro, MA, has indicated that this will affect its common stock, which has a par value of $0.0001 per share. The termination of registration and suspension of reporting duties were enacted in accordance with Rule 12g-4(a)(1) and Rule 15d-6, as marked on the form. As of the notice date, eFFECTOR Therapeutics reported approximately 49 holders of record. The certification was signed by Craig R. Jalbert on July 30, 2024, on behalf of eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics, Inc. has officially filed a Form 15 with the United States Securities and Exchange Commission (SEC) to terminate its registration under Section 12(g) of the Securities Exchange Act of 1934 and to suspend its duty to file reports under Sections 13 and 15(d) of the same act. The company, with its principal executive offices located at 124 Washington Street, Suite 101, Foxboro, MA, has indicated that this will affect its common stock, which has a par value of $0.0001 per share. The termination of registration and suspension of reporting duties were enacted in accordance with Rule 12g-4(a)(1) and Rule 15d-6, as marked on the form. As of the notice date, eFFECTOR Therapeutics reported approximately 49 holders of record. The certification was signed by Craig R. Jalbert on July 30, 2024, on behalf of eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics公司已經正式向美國證券交易所(SEC)提交了Form 15，以終止其在1934年證券交易法第12(g)條下的註冊，並暫停根據同一法案的第13和第15(d)條的報告義務。該公司的總部位於124 Washington Street，Suite 101，Foxboro，MA，它表示這將影響其每股面值爲0.0001美元的普通股。註冊終止和報告職責的暫停符合第12g-4(a)(1)條和第15d-6條的規定，這在表格中有標註。截至公告日期，eFFECTOR Therapeutics報告了約49個持股人。該證明書於2024年7月30日由Craig R. Jalbert代表eFFECTOR Therapeutics公司簽署。
eFFECTOR Therapeutics公司已經正式向美國證券交易所(SEC)提交了Form 15，以終止其在1934年證券交易法第12(g)條下的註冊，並暫停根據同一法案的第13和第15(d)條的報告義務。該公司的總部位於124 Washington Street，Suite 101，Foxboro，MA，它表示這將影響其每股面值爲0.0001美元的普通股。註冊終止和報告職責的暫停符合第12g-4(a)(1)條和第15d-6條的規定，這在表格中有標註。截至公告日期，eFFECTOR Therapeutics報告了約49個持股人。該證明書於2024年7月30日由Craig R. Jalbert代表eFFECTOR Therapeutics公司簽署。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間